Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
17. Dezember 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breas
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
04. Dezember 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
03. Dezember 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
25. November 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
22. November 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
21. November 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
14. November 2024 16:15 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
06. November 2024 07:30 ET
|
Plus Therapeutics Inc.; Spectron RX
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
05. November 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
29. Oktober 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas